Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Feb;5(2):320-331.
doi: 10.1038/s43587-024-00775-0. Epub 2024 Dec 13.

The CALERIE Genomic Data Resource

Affiliations
Randomized Controlled Trial

The CALERIE Genomic Data Resource

C P Ryan et al. Nat Aging. 2025 Feb.

Abstract

Caloric restriction (CR) slows biological aging and prolongs healthy lifespan in model organisms. Findings from the CALERIE randomized, controlled trial of long-term CR in healthy, nonobese humans broadly supports a similar pattern of effects in humans. To expand our understanding of the molecular pathways and biological processes underpinning CR effects in humans, we generated a series of genomic datasets from stored biospecimens collected from n = 218 participants during the trial. These data constitute a genomic data resource for a randomized controlled trial of an intervention targeting the biology of aging. Datasets include whole-genome single-nucleotide polymorphism genotypes, and three-timepoint-longitudinal DNA methylation, mRNA and small RNA datasets generated from blood, skeletal muscle and adipose tissue samples (total sample n = 2,327). The CALERIE Genomic Data Resource described in this article is available from the Aging Research Biobank. This multi-tissue, multi-omics, longitudinal data resource has great potential to advance translational geroscience. ClinicalTrials.gov registration: NCT00427193 .

PubMed Disclaimer

Conflict of interest statement

Competing interests: D.W.B. and D.L.C. are listed as inventors of the Duke University and University of Otago invention DunedinPACE, which is licensed to TruDiagnostic. D.W.B. is consulting CSO and SAB chair of BellSant and serves on the SAB of the Hooke Clinic. The Regents of the University of California are the sole owner of patents and patent applications directed at epigenetic biomarkers for which S.H. is a named inventor; S.H. is a founder and paid consultant of the non-profit Epigenetic Clock Development Foundation that licenses these patents. S.H. is a Principal Investigator at the Altos Labs, Cambridge Institute of Science, a biomedical company that works on rejuvenation. The remaining authors declare no competing interests.

Figures

Extended Data Figure 1.
Extended Data Figure 1.
The figure shows an upset plot displaying overlap of available datasets across treatment group, tissues, molecular data type. This figure is analogous to Figure 2, Panel A in the main manuscript, with the exception that here only samples with baseline and at least one follow-up (12- or 24-months) are counted. The left-hand side shows tissue type (blood, muscle, or adipose), type of molecular data type (SNPs, DNAm, smRNAs, or mRNA), set size for each tissue and data type combination in number of unique individuals, and group (CR or AL). The bottom right-hand side shows points and connecting lines indicating overlapping intersections across tissues and data types color coded by treatment group (CR = red, AL = navy). The top right hand side shows a barchart indicating sample sizes for the overlapping intersections of tissue and datatypes. Each tissue and molecular data type combination is linked to a corresponding color scheme as follows: genomic variation (purple DNA), blood DNA methylation (red DNA with lollipops), blood small RNAs (smRNAs; dark red RNA fragments), muscle DNA methylation (blue DNA with lollipops), muscle smRNAs (blue RNA fragments), muscle mRNA (blue single RNA strand), adipose DNA methylation (yellow DNA with lollipops), adipose smRNAs (yellow RNA fragments), adipose mRNA (yellow single RNA strand).
Extended Data Figure 2.
Extended Data Figure 2.
The figure shows estimated adipose, epithelial, fibroblast, and immune cell proportions for blood (Panel A; n=594), muscle (Panel B; n=168), and adipose (Panel C; n=161) tissue samples. For each tissue type, individual points represent individual samples. Proportion of cell types are shown as box and whisker plots showing median (horizontal line), 25th quartile (bottom of the box), 75th quartile (top of the box), and minimum and maximum values within 1.5 × IQR (interquartile range; top and bottom segments, respectively). Adipose cell types are colored in gold, epithelial cells are colored in blue, fibroblasts are colored in seagreen, and immune cells are colored in coral. Estimated cell proportions are based on DNA methylation and the hierarchical EpiDISH deconvolution method described in Zheng et al. 2018.
Extended Data Figure 3.
Extended Data Figure 3.. Associations of DNA methylation measures of aging with chronological age.
The figure shows DNA methylation measures of aging (Y-axis) against chronological age (X-axis) for n=212 men and women at pre-intervention baseline. The dashed colored line on each facet is the line of identity (intercept=0, slope=1), indicating where predicted epigenetic age or pace of aging would equal chronological age. Correlations with chronological age are as follows: Horvath Clock r=0.87, PC Horvath Clock r=0.84, Hannum Clock r=0.92, PC Hannum Clock r=0.88, Skin & Blood Clock r=0.94, PC Skin & Blood Clock r=0.80, PhenoAge Clock r=0.84, PC PhenoAge Clock r=0.85, GrimAge Clock r=0.93, PC GrimAge Clock r=0.92, DunedinPACE r=0.15.
Extended Data Figure 4.
Extended Data Figure 4.. Associations of age-residualized DNA methylation measures of aging with each other.
The figure shows correlations between age-residualized DNA methylation measures of aging for n=212 men and women at pre-intervention baseline with each other. The dashed red line on each facet is the fitted regression slopes. Pearson correlations between DNA methylation measures of aging are shown on the upper diagonal facets, with the shade of the facet indicating the strength of the correlation.
Extended Data Figure 5.
Extended Data Figure 5.
Average intensity of methylated (x-axis) and unmethylated (y-axis) signals for DNAm from blood (n=594) relative to signal intensity of 10.5. Each sample is represented by a point, with samples from the Ad Libitum treatment group colored blue and samples from caloric restriction treatment group colored red.
Extended Data Figure 6.
Extended Data Figure 6.
Average detection p-value for DNAm sampled from blood (n=594) relative to p-value of 0.05 (red dotted vertical line).
Extended Data Figure 7.
Extended Data Figure 7.
Average intensity of methylated (x-axis) and unmethylated (y-axis) signals for DNAm from muscle tissue (n=168) relative to signal intensity of 10.5. Each sample is represented by a point, with samples from the Ad Libitum treatment group colored blue and samples from caloric restriction treatment group colored red.
Extended Data Figure 8.
Extended Data Figure 8.
Average detection p-value for DNAm sampled from muscle (n=168) relative to p-value of 0.05 (red dotted vertical line).
Extended Data Figure 9.
Extended Data Figure 9.
Average intensity of methylated (x-axis) and unmethylated (y-axis) signals for DNAm from adipose tissue (n=168) relative to signal intensity of 10.5. Each sample is represented by a point, with samples from the Ad Libitum treatment group colored blue and samples from caloric restriction treatment group colored red.
Extended Data Figure 10.
Extended Data Figure 10.
Average detection p-value for DNAm sampled from adipose (n=161) relative to p-value of 0.05 (red dotted vertical line).
Figure 1.
Figure 1.. Study design, participant information, and overview of molecular datasets generated for the CALERIE caloric restriction trial.
Panel A shows the Consort diagram showing enrollment, eligibility, and final sample sizes by treatment group. Panel B shows a schematic of molecular data types and tissue sources. Genetic material (DNA) was derived from blood samples for both ad libitum (AL) and caloric restriction (CR) groups at baseline. DNA methylation was derived from blood, muscle, and adipose samples for both AL and CR at baseline, 12-months, and 24-months. Small RNAs were derived from blood, muscle, and adipose samples for both AL and CR at baseline, 12-months, and 24-months. mRNA was derived from muscle and adipose samples for both AL and CR at baseline, 12-months, and 24-months. Panel C shows a table of demographic information for participants that contributed data to individual tissue level molecular datasets. Total sample size, mean and standard deviation in age, age range, percent female, percent who self-reported as other than white, and mean and standard deviation of BMI.
Figure 2.
Figure 2.
Panel A shows an upset plot showing overlap of available datasets across treatment group, tissues, molecular data type. The left-hand side shows tissue type (blood, muscle, or adipose), type of molecular data type (SNPs, DNAm, smRNAs, or mRNA), set size for each tissue and data type combination in number of unique individuals, and group (CR or AL). The bottom right-hand side shows points and connecting lines indicating overlapping intersections across tissues and data types color coded by treatment group (CR = red, AL = navy). The top right hand side shows a barchart indicating sample sizes for the overlapping intersections of tissue and datatypes. Each tissue and molecular data type combination is linked to a corresponding color scheme as follows: genomic variation (purple DNA), blood DNA methylation (red DNA with lollipops), blood small RNAs (smRNAs; dark red RNA fragments), muscle DNA methylation (blue DNA with lollipops), muscle smRNAs (blue RNA fragments), muscle mRNA (blue single RNA strand), adipose DNA methylation (yellow DNA with lollipops), adipose smRNAs (yellow RNA fragments), adipose mRNA (yellow single RNA strand). Panel B shows Individual sample numbers by molecular data type, treatment group (Caloric Restriction or Ad Libitum) and follow-up visit (Baseline, 12 Month, or 24 Month) across different tissue types. For some individuals, samples were available at follow-up but not baseline (or vice versa), so baseline numbers for a tissue and treatment group combination will not always match sample sizes in Figure 2 Panel A.
Figure 3.
Figure 3.. SNP-based principal components scores for CALERIE participants.
The figure shows the top two SNP-based principal components (PCs) for CALERIE participants (n=217), colored by self-reported race/ethnicity. Dashed lines indicate three standard deviations from the mean for participants who self-reported race/ethnicity as White. The top-5 SNP-based principal-components explained 11.9% (PC1) 4.8% (PC2), 1.5% (PC3), 1.4% (PC4), and 1.3% (PC5) of the genetic variation among CALERIE participants.
Figure 4.
Figure 4.
Associations of DNA methylation measures of aging with chronological age and age-residualized DNA methylation measures of aging with each other. Panel A shows DNA methylation measures of aging (Y-axis) against chronological age (X-axis) for n=212 men and women at pre-intervention baseline. The dashed colored line on each facet is the line of identity (intercept=0, slope=1), indicating where predicted epigenetic age or pace of aging would equal chronological age. Correlations with chronological age are as follows: PC Horvath Clock r=0.84, PC Hannum Clock r=0.88, PC PhenoAge Clock r=0.85, PC GrimAge Clock r=0.92, DunedinPACE r=0.15. Panel B shows correlations between age-residualized DNA methylation measures of aging for n=212 men and women at pre-intervention baseline with each other. The dashed red line on each facet is the fitted regression slopes. Pearson correlations between DNA methylation measures of aging are shown on the upper diagonal facets, with the shade of the facet indicating the strength of the correlation.
Figure 5.
Figure 5.. Relative proportions of 12 white blood cell types estimated for all participants at baseline.
The figure shows the estimated relative proportions of 12 white blood cell types for all participants at baseline (n=216), prior to treatment (Bas=basophils, Bmem=memory B cells, Bnv=naïve B cells, CD4mem=memory CD4T cells, CD4nv=naïve CD4T cells, CD8mem=memory CD8T cells, CD8nv=naïve CD8T cells, Eos=Eosinophils, Mono=Monocytes, NK=Natural Killer cells, Treg=T regulatory cells, Neutrophils=Neutrophil cells). Individual points represent individual observations. Box and whisker plots showing median (horizontal line), 25th quartile (bottom of the box), 75th quartile (top of the box), and minimum and maximum values within 1.5 × IQR (interquartile range; top and bottom segments, respectively). Neutrophils are plotted on a separate scale.
Figure 6.
Figure 6.
Differences in adipose mRNA expression (A and C) and enriched biological processes (B and D) between CR and AL groups at the 12-month and 24-month timepoints. For Panels A and C, x-axis shows log2 fold-change differences between groups. The y-axis shows −log10 p-value. Blue points show genes with false-discovery rate q-values less than 0.05 were downregulated in CR participants. Red points show genes with false-discovery rate q-values less than 0.05 were upregulated in CR participants. Gray points show genes with q-values equal or greater than 0.05. Using a false-discovery cutoff of q=0.05, a total of 605 genes (from 19471 genes total) were differentially-expressed between CR and AL treatment groups at the 12-month timepoint (n=34, Panel A) and 734 genes were differentially-expressed between CR and AL treatment groups at the 24-month timepoint (n=18, Panel C). A dispersed but otherwise arbitrary selection of 31 differentially-expressed genes labeled by gene symbol are shown for the 12-month treatment effect. A dispersed but otherwise arbitrary selection of 23 differentially-expressed genes labeled by gene symbol are shown for the 24-month treatment effect. Panels B and D show the top-10 upregulated (red) and down-regulated (blue) biological pathways from Gene Ontology based on overlapping results from both fast GSEA and GAGE gene set enrichment. The full set of enriched pathways for 12-month and 24-month follow-ups are in Tables S2 and S3, respectively.

Update of

References

    1. Bales CW & Kraus WE Caloric Restriction: IMPLICATIONS FOR HUMAN CARDIOMETABOLIC HEALTH. Journal of Cardiopulmonary Rehabilitation and Prevention 33, 201 (2013). - PMC - PubMed
    1. Speakman JR & Mitchell SE Caloric restriction. Molecular Aspects of Medicine 32, 159–221 (2011). - PubMed
    1. Fontana L, Meyer TE, Klein S & Holloszy JO Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proceedings of the National Academy of Sciences 101, 6659–6663 (2004). - PMC - PubMed
    1. Meyer TE et al. Long-Term Caloric Restriction Ameliorates the Decline in Diastolic Function in Humans. Journal of the American College of Cardiology 47, 398–402 (2006). - PubMed
    1. Heilbronn LK et al. Effect of 6-Month Calorie Restriction on Biomarkers of Longevity, Metabolic Adaptation, and Oxidative Stress in Overweight IndividualsA Randomized Controlled Trial. JAMA 295, 1539–1548 (2006). - PMC - PubMed

Publication types

Associated data